In connection with Isofol's intention to conduct a fully guaranteed rights issue of units, the company´s CEO, Petter Segelman Lindqvist, narrates about the background, terms and future plans in an interview with Redeye. The interview (in Swedish) is available at the link below and on Isofol's web site.

Link to the interview >>

For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer 
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56

The information was submitted for publication, through the agency of the contact person set out above, at 08:15 CEST on May 14, 2025.

About Isofol Medical AB (publ)
Isofol Medical AB (publ) works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that are expected to optimize the effect of the drug candidate.
Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
www.isofolmedical.com